Integral Health Asset Management’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-250,000
Closed -$8.13M 117
2026
Q1
$8.13M Buy
250,000
+150,000
+150% +$4.82M 0.39% 68
2025
Q4
$3.52M Buy
+100,000
New +$3.54M 0.17% 77
2025
Q1
Sell
-150,000
Closed -$4.74M 109
2024
Q4
$6.04M Buy
+150,000
New +$8.55M 0.51% 57
2024
Q3
Sell
-250,000
Closed -$14.7M 101
2024
Q2
$13.3M Sell
250,000
-200,000
-44% -$13.1M 1.26% 27
2024
Q1
$36.9M Sell
450,000
-50,000
-10% -$2.22M 3.43% 3
2023
Q4
$9.3M Sell
500,000
-300,000
-38% -$3.92M 1.27% 36
2023
Q3
$8.86M Buy
800,000
+70,000
+10% +$1M 1.23% 32
2023
Q2
$11.8M Buy
730,000
+2,900
+0.4% +$60.8K 1.47% 28
2023
Q1
$12.1M Buy
727,100
+127,100
+21% +$1.31M 2.44% 8
2022
Q4
$5.64M Buy
+600,000
New +$2.68M 1.18% 33

Other funds holding VKTX

Integral Health Asset Management's VKTX Position: Q2 2026 in Review

Integral Health Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 250,000 shares — an estimated $8.13M sold.

Integral Health Asset Management first reported a position in VKTX in Q4 2022 and held it in 10 quarters. The position peaked at $36.9M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Integral Health Asset Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Integral Health Asset Management sold 250,000 Viking Therapeutics shares in Q2 2026, an estimated $8.13M.
  • Integral Health Asset Management first reported a position in Viking Therapeutics in Q4 2022 and held it in 10 quarters.
  • Integral Health Asset Management's Viking Therapeutics position peaked at $36.9M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.